Introduction

Background on the disease
Craniosynostosis, the premature fusion of the cranial sutures, is a serious disorder with a prevalence of ~1 in 2,200 children. There are over 30 known disease genes, with dominantly acting mutations in the FGFR2, FGFR3, TWIST1 and EFNB1 genes accounting for most of the 20-25% of cases with a single genetic aetiology 1 .
Case study
The female proband, CRS_4659, was noted to have microcephaly in utero, and craniosynostosis was suspected based on magnetic resonance imaging performed at 30 weeks' gestation. She was born at term by planned Caesarean section, and did not require any resuscitation. On formal craniofacial assessment at the age of 7 weeks, a very tall skull with a marked transverse occipital constriction and multiple palpable soft spots was noted. She was dysmorphic with exorbitsm, slightly upslanting palpebral fissures and arched eyebrows. She had a high arched palate and thin upper lip; the ears, hands and feet were normal. Three dimensional computed tomographic analysis of the skull showed multiple widespread craniolacunae and synostosis of all sutures ( Figure 3A ). She underwent an occipital craniectomy and foramen magnum decompression at 7 months of age and a fronto-orbital advancement at 4 years of age. Formal developmental assessment prior to the second procedure indicated that she was performing in the low average range of ability, with decreased attention and concentration and marked distractibility. Speech and language assessment using Clinical Evaluation of Language Fundamentals (CELF) Preschool gave scores in the 3-6 range (average 10).
Known genes/pathways and prior screens
The clinical picture was not reminiscent of craniosynostosis disorders caused by known disease mutations. Analysis of blood for disorders of bone biochemistry (Ca, P, Mg, alkaline phosphatase), a craniosynostosis disease gene screen (for mutation hotspots/deletions in FGFR1, FGFR2, FGFR3, TWIST1 and EFNB1), karyotyping and array comparative genomic hybridisation screen (Agilent 250k) were all normal.
Experimental design and strategy for identifying candidates
We sequenced the proband and her unaffected parents. They were nonconsanguineous, and there was no family history of craniosynostosis. We suspected a de novo, dominant mutation (because the majority of monogenic craniosynostosis exhibits dominant genetics), but also considered recessive mechanisms. We searched for de novo variants in the proband, absent in the parents, and prioritised exonic mutations predicted to cause alterations in the encoded protein.
Methods for follow-up studies
Parental origin of the mutation
We designed allele-specific primers to determine whether the child's HUWE1 mutation was present on the allele of maternal or paternal origin. We exploited two closely adjacent intronic C/A polymorphisms at positions chrX:53,675,478 and chrX:53,675,488, ~1150 bp upstream of the HUWE1 mutation, that we had identified in the whole genome sequence. The proband and her mother (CRS_4654) were heterozygous (CC/AA), whilst the father (CRS_4655) was a CC hemizygote (Supplementary Figure 7 left ). Allele-specific primers CCRev (5'-CCAAGGTGGGTTTTT GTTTTGTTTTTTGTTTTGTTTTGTTTTG-3') and AARev (5'-CCAAGGTGGGTTTTTGTTTTGTTTTTTGTTT TTTTTTGTTTTT-3') were designed to amplify the CC and AA alleles respectively (bases differing between the two primers italicised). PCR was carried out using either CCRev or AARev and a common forward primer Intron6-For (5'-CCCATCAACCCTATGAAGGATAGTATCTATATCC-3'), so that the product spanned exons 5 and 6 (containing the HUWE1 mutation). The AARev primer did not generate a product using the paternal sample, confirming that amplification was allele-specific (Supplementary Figure 7 , top gel pictures). The 1392 bp amplification product was digested with HpaII, for which a restriction site is ablated by the HUWE1 mutation. The 645 bp fragment characteristic of the mutant allele was observed only in DNA amplified from the child using the CCRev primer (Supplementary Figure 7 , bottom gel picture, white arrow), indicating that the mutation resided on the paternal allele ( Figure 3B ).
X inactivation studies for HUWE1 mutation
Skewing of X inactivation was measured using the androgen receptor gene (AR) triplet repeat assay 2, 3 . Briefly, 1 µg of genomic DNA was predigested with RsaI either in the presence (+) or absence (-) of the methylation-sensitive enzyme HpaII (20 U). PCR amplification was carried out using primers AR-For (5'-TCCAGAATCTGTTCCAGAGCGTGC-3') and AR-Rev (5'-FAM-GCTGTGAAGGTTGCTGTTCCTCAT-3'). Amplicons were analysed on an ABI 3130 sequencer and sized using GeneScan software. Differences in peak areas for the two alleles in the HpaII(+) assay were corrected for differences in amplification efficiency measured in the HpaII(-) assay, and the final results expressed as a percentage of the more inactivated allele. Of note, Platypus was unable to specify the correct AR triplet repeat genotypes in heterozygotes (not shown), highlighting the difficulties of accurately calling simple sequence repeats using 100 bp read data.
Analysis of HUWE1 expression
RNA was extracted from EBV-transformed lymphoblastoid cells and scalp fibroblasts obtained from patient CRS_4659. cDNA was synthesised using the Fermentas RevertAid First-Strand Synthesis kit with random hexamer primers according to the manufacturer's instructions. PCR amplification was carried out using primers Ex6Rev (5'-CTGCCAGCACCACTTGCATATCAGAGGAAGCC-3') and Ex5For (5'-GTGCGAGTTATATCACTGGGTGGACCTGTTGG-3') to generate a product of 257 bp. HpaII digests the normal but not the mutant product, generating fragments of 186 and 71 bp.
Results
Amongst 94 de novo mutations identified in the proband, a mutation at chrX:53,674,333 in the HUWE1 gene (c.329G>A encoding p.Arg110Gln) was the only one predicted to alter protein coding. HUWE1 encodes a ubiquitin ligase, and the mutation resides at a highly conserved position (including across invertebrates and yeasts) of the DUF908 domain, the function of which is unknown (http://pfam.sanger.ac.uk/family/duf908) (Supplementary Figure 7 , bottom right). Five missense mutations elsewhere in the protein were previously reported in pedigrees segregating X-linked mental retardation or autistic spectrum disorder [4] [5] [6] . In two of these pedigrees, female carriers were reported to be symptomatic and/or to have associated macrocephaly.
The mutation was found to originate from the paternal X chromosome (Supplementary Figure 7 , bottom gel picture). To seek additional support for an X-linked origin of the child's disorder, we studied X-inactivation, because (owing to negative selection of cells lacking a functional gene copy), female carriers of many serious X-linked disorders exhibit preferential inactivation of the X chromosome bearing the mutant allele 7 . Indeed, we found that the proband exhibited extreme skewing of X-inactivation ( Figure 3C ), but to our surprise the maternal (and therefore non-mutant) X was preferentially inactivated. Corroborating this conclusion, RNA expression studies in scalp fibroblasts and EBV-transformed lymphoblastoid cells showed that only mutant HUWE1 is expressed in the patient ( Figure 3D ). Neither the mother nor the paternal grandmother showed extreme skewing of X-inactivation ( Figure 3C ), ruling out the possibility that one of the proband's X chromosomes was constitutionally susceptible or resistant to X-inactivation.
We considered the possibility that a different de novo mutation, occurring on the maternally inherited X chromosome, could have led to selective inactivation of the maternal X. We therefore scrutinised the seven other X-encoded de novo mutations that had been detected by WGS ( Figure  3E ). Three variants located within genes (all noncoding): two were shown to be present on the paternal allele whilst the third, for which parental origin could not be determined, was in a gene (CCDC160) that is in a region not subject to X-inactivation 8 . Of the other four de novo variants, all were found in SINE or LINE repeats, and appeared unlikely to be functionally significant.
In addition, we scrutinised the X chromosome for regions in which a maternal allele was apparently not transmitted, as this could indicate a de novo deletion on the maternal allele. We identified two such regions, one (chrX:5,055,376-5,057,467) in an intergenic region at Xp22.1, and the other (chrX:154,778,278-154,784,971) within intron 1 of TMLHE at Xq28. These copy number changes did not appear to be good candidates to cause the skewed X-inactivation.
We used dideoxy-sequencing to screen 280 patients with craniosynostosis for mutations of HUWE1 located within the region encoding the DUF908, but found no other significant mutations. In addition, we sequenced the entire HUWE1 gene in 47 patients with multisuture synostosis using Fluidigm Access Array multiplexing and Ion Torrent sequencing, but again found no likely pathogenic mutations. However, we did subsequently identify, using exome sequencing, a different de novo hemizygous mutation altering the same amino acid of HUWE1 (c.328C>T encoding p.R110W) in a boy presenting with metopic craniosynostosis, moderate-severe learning disability and other dysmorphic features, making us confident that this mutation was pathogenic in both cases.
Clinical actions
There is strong evidence that the mutation is the cause of the child's learning disability and craniosynostosis, because (1) HUWE1 is an established disease gene in X-linked mental retardation in males 4, 6 , and (2) a de novo mutation at the same codon was found by exome sequencing in a male patient who presented with craniosynostosis.
The parents requested help with obtaining special educational support for their daughter, so a letter outlining the genetic diagnosis and its likely contribution to the learning disability was written to the education authorities. A suitable educational plan was subsequently implemented and the parents considered the genetic information to be instrumental in this outcome.
EPO in erythrocytosis
Introduction
Background on the disease
Erythrocytosis is a clinical condition characterized by increased red cell mass and typically elevated haematocrit and haemoglobin (Hb) concentration 9 . It can be congenital (e.g. genetic) or acquired. In primary erythrocytosis, patients have an intrinsic defect in the erythroid cells of the bone marrow and typically have low levels of erythropoietin (Epo), the protein that promotes the survival, proliferation and differentiation of erythrocyte progenitor cells. In secondary erythropoiesis, the increased red cell production is driven by external factors (e.g. hypoxia or defects in oxygen sensing) through increased erythropoietin production, and patients typically have high or inappropriately normal Epo levels 9 . Epo production is controlled at the transcriptional level in an oxygen-regulated manner. This control is mediated by hypoxia-inducible transcription factors (HIF), and mutations in genes in the HIF pathway are known to cause erythrocytosis 10 
.
Even after screening for all known mutations, there remains a considerable number of patients in whom no genetic cause has been found 11 . Of these patients with idiopathic erythrocytosis, about two thirds have inappropriately normal or elevated levels of erythropoietin (given their level of Hb), suggesting a high likelihood of a defect in their oxygen-sensing pathway. Furthermore, most of these patients have early-onset (childhood) disease and often have a family history (sometimes with clear patterns of Mendelian inheritance), suggesting a high probability for an underlying genetic aetiology.
Case study
Two unrelated families, Family M and Family S, were identified showing an autosomal dominant pattern of erythrocytosis inheritance ( Figure 4B ). The patients with erythrocytosis had raised Hb concentrations (>16.5 g/dl in females and >18.5 g/dl in males) and haematocrits (>0.5 l/l), had high Epo levels and were diagnosed at young age, some as young as 2 years of age (e.g. PAR07 and PAR08).
Known genes / pathways and prior screens
Our investigations focused on patients with idiopathic erythrocytosis with either high or inappropriately normal Epo levels, suggesting a defect in oxygen sensing rather than primary erythrocytosis. Based on knowledge of the biological pathway for hypoxia induced erythrocytosis, a list of a priori candidate genes included: HIF1A, EPAS1 (HIF2A), HIF3A, ARNT (HIF1B), HIF1AN (FIH), EGLN1 (PHD2), EGLN2 (PHD1), EGLN3 (PHD3), VHL, EPO, HBB, HBA1, HBA2, BPGM. We also considered JAK2 and EPOR as candidates, since these are involved in congenital erythrocytosis.
Known exonic mutations in VHL, PHD2, HIF2A, EPOR and JAK2, were screened for prior to genome sequencing, and found to be absent.
Experimental design and strategy for identifying candidates
In family S, DNA samples were available from six individuals both from affected and unaffected family members ( Figure 4B ). WGS was performed on two affected individuals (PAR09 and PAR07), and on one unaffected (PAR18), forming a trio. DNA from one affected (PAR08) and 2 unaffected members (PAR19 and PAR 22) were used in follow-up genotyping and segregation analysis. We did not have any information on, nor could we collect DNA from, the father of PAR09.
In family M, DNA samples were available for four individuals. WGS was performed on two affected individuals (PAR15 and PAR16), and DNA from one affected (PAR17) and one unaffected (PAR20) members were used in follow-up genotyping and segregation analysis.
In both families, the disease appeared to follow a dominant inheritance pattern and so we focused on heterozygous variants shared between affecteds, but not unaffecteds, in each family individually. As all individuals have large numbers of these, we prioritized known candidate genes. We originally looked at coding candidates, but later extended this to noncoding exonic sequence.
Results
None of our candidate genes contained coding mutations that segregated with disease. However, we identified a single nucleotide variant (G>A) in the 5'UTR of EPO at chr7:100,318,468, shared by the affected individuals in the 2 families (PAR07 and PAR09 in family S, PAR15 and PAR16 in family M). The variant was not found in PAR18 nor in other WGS500 samples. Sanger sequencing confirmed the presence of the 5'UTR variant in the affected members of Family M (PAR17, PAR15, PAR16) and Family S (PAR09, PAR07, PAR08) and its absence in unaffected members of either family (Family S: PAR 18, PAR19, PAR22; Family M: PAR20).
The EPO variant is not listed in dbSNP, 1000 Genomes, or any other samples sequenced within the WGS500 project. In order to determine whether the variant had arisen independently in the two families, we analysed the surrounding SNVs in the family members for which genomic sequence was available. This revealed 47 rare variants (1000 Genomes frequency < 1%) that are found, uniquely (within the WGS500 project) in the four affected individuals, in an approximately 8 Mb region (chr7:93,533,251-100,993,241). This provides compelling evidence that the region is identical-bydescent in both families and that the 5'UTR variant had one common origin. The 5'UTR variant is the only exonic variant and EPO the only candidate gene in this 8 Mb region. No other genomic region in the two families shows a similar pattern of sharing of rare variants. This suggests that the haplotype carrying the variant is multiple generations old, and thus likely to be found in others. This finding will be followed-up by screening larger cohorts of patients with idiopathic erythrocytosis for this 5'UTR variant and by functional molecular studies to investigate the mechanism of action of this mutation. The putative functional variant lies in a small conserved block within the EPO 5'UTR ( Figure 4A ), and so it seems likely to affect expression.
Clinical actions
WGS has played an important diagnostic role in clarifying the aetiology of the disease in these two families with erythrocytosis. These findings will be useful in screening and family planning and counselling.
SOX3 in hypoparathyroidism
Introduction
Background on the disease
Hypoparathyroidism is an endocrine disorder in which deficiency of parathyroid hormone (PTH) results in hypocalcaemia that may be associated with tetany, carpopedal spasms, seizures, laryngeal stridor, cataracts or ectopic calcification. Treatment with oral vitamin D preparations and calcium supplements is effective at restoring normocalcaemia and ameliorating the neuro-muscular symptoms. Hypoparathyroidism may be congenital due to parathyroid gland agenesis (e.g. the DiGeorge syndrome) or acquired and due to destruction of the parathyroid glands (e.g. in autoimmune diseases). In addition, hypoparathyroidism may occur as part of a complex congenital syndrome (e.g. the DiGeorge syndrome or a pluriglandular autoimmune disorder) or as a nonsyndromic solitary endocrinopathy, which is referred to as isolated or idiopathic hypoparathyroidism. Familial occurrences of idiopathic hypoparathyroidism have been reported and autosomal dominant, autosomal recessive, and X-linked inheritances have been established. Genetic abnormalities of TBX1, AIRE1, GATA3, TBCE, GCMB, PTH, CASR, GNA11, SOX3 and the mitochondrial genome have been reported in patients with these syndromic and non-syndromic forms of hypoparathyroidism. The incidence of hypoparathyroidism has not been established, but DiGeorge syndrome is reported to occur in 1/3,000 live births and an autoimmune form of hypoparathyroidism has been reported to occur more often in the Finnish and Iranian-Jewish populations.
Case study
The proband, HPT_3, is the son of nonconsanguineous parents. He presented at age 9 months with seizures due to hypocalcemia (corrected serum calcium concentrations = 3.0 to 4.0 mg/dl; normal = 9.0 to 10.1 mg/dl) attributed to primary hypoparathyroidism. His grandfather, HPT_1, was also known to have had hypocalcemic seizures during childhood. Neither the proband nor his grandfather suffered from immunodeficiency, cardiac anomalies, craniofacial defects, developmental delay, deafness, or renal dysplasia. Thus, the findings seemed consistent with isolated hypoparathyroidism (HPT) that was likely inherited as an X-linked recessive trait. Treatment with vitamin D preparations and oral calcium supplements restored normocalcaemia.
Known genes/pathways and prior screens
Genetic abnormalities involving the coding regions of the GCMB, PTH, CASR, SOX3, and AIRE1 have been previously excluded. A previous report of familial hypoparathyroidism implicated a deletioninsertion near SOX3 on chromosome X via linkage analysis 12 . The report identified a region from 2p25.3 inserted at Xq27.1 with simultaneous deletion of a region from chromosome X. It also demonstrated Sox3 expression in the developing parathyroid tissue of mouse embryos.
Experimental design and strategy for identifying candidates
The genomes of the proband, HPT_3, and his affected grandfather, HPT_1, were sequenced. DNA from the proband's unaffected mother, HPT_2, and brother, HPT_4, was used in follow-up genotyping. The pattern of inheritance clearly suggested that the pathogenic variant was X-linked, and SOX3, previously linked to hypoparathyroidism, was the main candidate gene. Accordingly, we searched for mutations and larger structural variants in and around SOX3.
Results
Visual inspection of reads mapping downstream of SOX3 showed an apparent deletion of 1.4 kb of X chromosomal sequence, located approximately 81.5 kb downstream of the gene. The pairs of reads flanking this deletion consistently mapped to either end of an approximately 50 kb sequence on chromosome 2p (Figure 4C ), suggesting a simultaneous deletion of an X chromosomal region with an insertion into the X chromosome of the region from 2p.
We used PCR to confirm the chromosomal rearrangement in the affected individuals ( Figure 4D The rearrangement breakpoints are distinct from the previously reported kindred 12 , suggesting independent events, but they are in broadly similar regions, so the pathogenesis is likely to be similar.
Clinical actions
WGS has helped to elucidate the aetiology of the disease in this family with hypoparathyroidism. This finding will be useful in counselling and screening of relatives. The number of putative simple recessive (i.e. homozygous) protein-altering variants (ANNOVAR annotation) in trio and quartet children under different filtering strategies. When segregation is ignored, this is simply the number of rare homozygous coding variants as defined by their frequency in the control datasets indicated. In order to classify the variant as recessive, the parents were both required to be heterozygous (in the raw calls). Manual inspection revealed that many of the homozygous variants filtered out using the other WGS500 samples tended to be in low complexity regions which are prone to spurious or incorrect calls, or have very low coverage. + Note that the mean excludes HCM_2361, MR_6 and MR_8 because of suspected sample contamination, EOE_5 due to a uniparental disomy for chromosome 9, and EOE_12 due to consanguinity. Results from two-sided Fisher's exact tests for a difference in the frequency of pseudo-candidate variants in candidate genes between trio probands and controls. Note that the numbers in each row do not add to 216 (the total number of individuals included in Figure 2 ), since related unaffected individuals were excluded from the control set, as were the individuals in the EOE quartet, because they might be expected to carry variants in these genes too. 
Supplementary references
Disease
Acquired essential thrombocytosis
THPO
splicing The same variant (NM_001177598: c.13+1G>C) has been described in two families before 13, 14 and arose independently. Wiestner et al. showed that it leads to skipping of exon 3 in the 5' UTR, which increased thrombopoietin protein causing enhanced megakaryopoiesis and thus increased platelet count in the affected individual 15 . This variant was used clinically: additional family members were screened, provided with counselling and offered appropriate haematology follow up. . This mutation (NM_002295.4:c.-34+5G>C ) leads to an impaired splicing at the end of exon 1 of RPSA, producing an insertion of 70bp in 80% of the transcripts coming from that allele. Overall the mutation leads to a 40% reduction of the RPSA protein level.
N/A
Cerebellar ataxia
SPTBN2 nonsense This is a homozygous stop mutation (NM_006946:c.1881C>A:p.C627X), and a mouse knock out has the same phenotype. Another family with a different homozygous stop mutation and identical phenotype and additional cases with truncating mutations have been published 17, 18 . The family have requested consideration for using this for prenatal diagnosis.
19
Common variable immunodeficiency disorder a missense
This gene is part of the TNFR superfamily and involved in B cell activation and proliferation. This variant is associated with B cell defects in its homozygous and heterozygous state. Although there is published evidence for a functional B cell defect in carriers, there seems to be incomplete penetrance and we therefore consider that it contributes to, rather than causes the phenotype.
N/A
Congenital dyserythropoietic anaemia, type 1 C15ORF41 missense This variant (NM_001130010:c.533T>A:p.L178Q) was present in all 3 affected family members of this pedigree. A second homozygous missense change (Y94C) was later identified in the same gene in four further CDA-I patients from two unrelated pedigrees. C15ORF41 has been added to the genes resequenced in unexplained anaemia patients by the NHS diagnostic service and they have recently identified a further individual from an unrelated pedigree with CDA-I caused by the L178Q change identified in the WGS study. This makes a total of 8 individuals from 4 unrelated pedigrees with CDA-I caused by this gene and work is ongoing onto the pathogenic mechanism.
20
Congenital myasthenic syndrome ALG2 missense The recessive variant (NM_033087:c.203T>G:p.V68G) segregates with disease within the family: the parents and unaffected brother are heterozygous, the patient homozygous. Expression of the protein derived from patient muscle biopsy was severely reduced versus control muscle biopsies. Expression from cDNA encoding the ALG2 mutation in HEK293 cells showed severely reduced ALG2 protein expression versus controls. Information was used in the clinic for genetic counselling, and to provide appropriate treatment: a cholinesterase inhibitor (pyridostigmine) in combination with either salbutamol or ephedrine.
Craniosynostosis ZIC1 nonsense This patient had bicoronal synostosis and severe learning disability and was found to have a de novo nonsense mutation in ZIC1 (NM_003412.3: c.1163C>A: p.S388*). We found three other similar patients with de novo nonsense mutations in this gene, one by exome sequencing and two by resequencing it in 342 patients. The transcript escapes nonsense-mediated decay and cDNA constructs showed altered activity in biological assays. This information was used clinically.
N/A HUWE1 missense This patient had multisuture craniosynostosis and mild learning disability. A de novo missense mutation (NM_031407.6: c.329G>A:p.R110Q) was found in HUWE1, which was previously reported for mental retardation with craniofacial features. The mutation affects a very highly conserved residue in a domain of unknown function (DUF908). The gene is large, spanning 154,641 bp and comprising 84 exons, and, because of extensive heterogeneity in CRS, the contribution to the disease is likely to be low, and thus it was not surprising that we did not find any other HUWE1 mutations in a cohort of 47 unrelated cases with complex CRS. The mutation was shown to have originated on the paternal X chromosome ( Figure 3B and Supplementary Figure 7) . Unexpectedly, cells from the patient show preferential inactivation of the maternally inherited, wild-type X ( Figure 3C ) and, consistent with these two observations, only the mutant allele was expressed in the two tissues (fibroblast and transformed lymphoblasts) available for analysis ( Figure 3D ). Whilst this work was under review we identified, using exome sequencing, a different de novo hemizygous mutation altering the same amino acid of HUWE1 (c.328C>T encoding p.R110W) in a boy presenting with metopic craniosynostosis, moderate-severe learning disability and other dysmorphic features. See the supplementary text for further details.
N/A
Erythrocytosis
EPO noncoding
The same variant at a highly conserved base (NM_000799.2:c.-136G>A; Figure 4A ) within the 5' UTR of the erythropoietin gene EPO was identified in two independent families with erythrocytosis and cosegregated with the disease. EPO is a strong candidate gene for erythrocytosis as erythropoietin is essential for red cell production and increased erythropoietin levels lead to increased red cell mass, the hallmark of erythrocytosis. The genetic evidence for causality of this EPO variant is strong: it is the only rare exonic variant found in an extended (8 Mb) region that is identical-by-descent in the affected individuals in these two unrelated families (the only such region), suggesting that it had a single mutational origin. See the supplementary text for further details.
N/A BPGM missense The patient inherited this mutation (NM_001724:c.269G>A:p.R90H) from his mother, who was asymptomatic but had hemoglobin levels on the upper end of the normal range. Both he and his mother had significantly lower levels of BPGM in red blood cells. BPGM deficiency affects the hemoglobin-oxygen dissociation curve, which leads to less available oxygen, stimulating red cell production. Other erythrocytosis patients with BPGM deficiency have been reported, and the same residue is mutated in other patients. . SOX3 is a strong candidate since it is known to be involved in the development of the parathyroid gland 23 . Figure 11) , and a previously reported mutation at the same location (E767K) causes a similar phenotype (autosomal dominant hypocalcaemia) 24 . It was missed by prior sequencing in a UK research lab.
N/A
UMOD missense This variant (NM_001008389:c.410G>A:p.C137Y) co-segregates with disease in the family (Supplementary Figure 11) . The UMOD gene is well known in FJHN 25 , and this variant is located in a region in which multiple mutations have been observed before (cbEGF3). The variant was missed by prior sequencing in a non-UK research lab. . Both affected brothers inherited the mutation from their heterozygous mother, who is phenotypically normal. It lies in the highly conserved channel region, and electrophysiology experiments showed that it affects gating of the channel. Functional studies are underway, and further details will be disclosed in a subsequent publication. 
